

Adapted IHI Trigger Tool for Measuring Anticoagulant Related Adverse Drug Events

Anticoagulaı	nt - P	atient Reco	rd Review S	heet				•
Patient Name / Identification #:							J	Patient's Age:
Admission D	Date:				arge Date: _			
Anticoagula	nt Ac	dministered	l:					
□ Warfariı	· · · · · · · · · · · · · · · · · · ·					□ Edoxaba		□ Other:
☐ Heparin ☐ Rivaroxaban						□ Betrixab	an	Not an exhaustive list. Work with Pharmacists to add all anticoagulants.
□ Enoxaparin □ Apixaban								
			Anticoa	igulant Related	d Adver	se Drug Eve	nt (ADE) Triggers	3
Trigger Code	Clue/Symptom/Lab Test					Trigger Code	Clue/Symptom/Lab Test	
AC1	Rash/Itching/Diphenhydramine Administered					AC9	INR > 6	
AC2	Anaphylactic Reaction					AC10	Platelet Count <50,000	
AC3	Nausea/Vomiting/Antiemetic Administered					AC11	Emergent Glucagon Administration	
AC4	Hypotension					AC12	Abrupt Cessation of Medication	
AC5	Dizziness					AC13	Fall	
AC6	Lethargy					AC14	Heparin Induced Thrombocytopenia	
AC7	Vitamin K Administered					AC15	Abrupt Cessation of Medication	
AC8	PPT > 100 Seconds					AC16	Transfer to Higher Level of Care	
Other	Not an exhaustive List. Add others and adjust table as needed.							
Triggers Fou	ınd _	ADE Fo	Harm		Description of ADE		Anticongulant Administered	
(Code)		Yes	No	Category**	Description of ADL		OI ADE	Anticoagulant Administered
Total ADEs for this patient:								
Total number of doses of medications for this patient (if available):								

Category A-D: Did not cause harm

Category E: Temporary harm to the patient and required intervention

Category F: Temporary harm to the patient and required initial or prolonged hospitalization

Category G: Permanent patient harm

Category H: Intervention required to sustain life

Category I: Patient's death

References: IHI Trigger Tool for Measuring ADEs (www.ihi.org) and NCC MERP Index for Categorizing Medication Errors (https://www.nccmerp.org)

The effectiveness of this tool is dependent upon a quality medication reconciliation being performed at admission.

This resource is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$640,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official view of, nor an endorsement, by HRSA, HHS or the U.S. Government. For more information, please visit HRSA.gov.

^{**}Harm Category (adapted from NCC MERP Index):